CXCL1 and triple-negative breast carcinoma: CXCL1 expression is increased by chemotherapeutics such as the histone deacetylase (HDAC) inhibitor Belinostat in breast cancer cells [123], paclitaxel in triple-negative breast cancer cells [94] and in melanoma cells [124], 5-fluorouracil in murine 4T1 triple-negative breast cancer cells [125], oxaliplatin in colorectal cancer cells [126] and metastatic castration-resistant prostate cancer cells [127], epidoxorubicin in bladder cancer cells [128], doxorubicin in triple-negative breast cancer cells [129], and carboplatin in murine B16-F10 melanoma cells [130].